Prime Medicine is a biotechnology company committed to delivering a class of differentiated one-time curative genetic therapies, Prime Editors, to address a spectrum of diseases by deploying Prime Editing technology. Co.'s in-licensed Prime Editing technology has the ability to repair mutations. Prime Editors have two main components that act together to edit deoxyribonucleic acid (DNA): a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme, and a pegRNA, that targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. We show 5 historical shares outstanding datapoints in our PRME shares outstanding history coverage, used to compute PRME market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PRME market cap history over the course of time is important for investors
interested in comparing PRME's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PRME versus a peer is one thing; comparing
PRME market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PRME can fluctuate over the course of history.
With this page we aim to empower investors researching PRME by allowing them to research the PRME market cap history. |
Free PRME Email Alerts:
Video: The Importance of Market Cap
